Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Altimmune Inc 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 USA

https://altimmune.com Employees: 57 P: 240-654-1450

Sector:

Medical

Description:

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.

Key Statistics

Overview:

Market Capitalization, $K 392,917
Enterprise Value, $K 383,407
Shares Outstanding, K 130,105
Float, K 124,380
% Float 95.60%
Short Interest, K 26,485
Short Float 20.36%
Days to Cover 6.96
Short Volume Ratio 0.56
% of Insider Shareholders 4.40%
% of Institutional Shareholders 78.05%

Financials:

Annual Sales, $ 40 K
Annual Net Income, $ -88,090 K
Last Quarter Sales, $ 30 K
Last Quarter Net Income, $ -27,360 K
EBIT, $ -94,490 K
EBITDA, $ -96,240 K

Growth:

1-Year Return -45.86%
3-Year Return -28.44%
5-Year Return -78.43%
5-Year Revenue Growth -99.51%
5-Year Earnings Growth 47.64%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.27 on 03/05/26
Next Earnings Date 05/12/26
Earnings Per Share ttm -1.01
EPS Growth vs. Prev Qtr -28.57%
EPS Growth vs. Prev Year 18.18%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Most Recent Dividend 2.910 on 02/06/17
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 09/14/18

ALT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -49.35%
Return-on-Assets % -41.65%
Profit Margin % -220,225.00%
Debt/Equity 0.15
Price/Sales 10,154.54
Price/Cash Flow N/A
Price/Book 1.61
Book Value/Share 1.99
Interest Coverage -53.13
60-Month Beta 0.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.